KMDA

NEUTRAL

$8.49 Live

Kamada Ltd. · NASDAQ

Target $13.0 (+53.1%)

$6.15 52W Range $9.35

KMDA Kamada Ltd. - Fundamental Analysis

NEUTRAL

Console Chart News

KMDA Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic

Current Price Live

$8.49

Analyst Target

$13.0

+53.1% Upside

52W High

$9.35

52W Low

$6.15

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 13, 2026

Market cap

$490.86M

P/E

24.26

ROE

7.6%

Profit margin

11.2%

Debt/Equity

0.04

Dividend yield

2.94%

AI Analysis

AI-powered fundamental assessment

Confidence

80%

KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.

Key Strengths

Exceptional liquidity with a Current Ratio of 4.07

Negligible leverage with Debt/Equity at 0.04

Strong PEG ratio (0.63) indicating potential growth undervaluation

Consistent double-digit revenue growth (14.50% YoY)

Strong long-term price appreciation (95.6% over 3 years)

Key Risks

Significant disconnect between current price ($8.49) and Intrinsic Value ($2.45)

Negative earnings growth (-14.10% YoY) despite revenue gains

Bearish technical trend (0/100 score)

Low insider sentiment (40/100)

High volatility in quarterly earnings surprises

AI Fair Value Estimate

Based on comprehensive analysis

$7.15

-15.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Strong

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Hold

Key drivers: Fortress balance sheet, Revenue growth, Valuation premium over deterministic baselines, Earnings contraction

Confidence

85%

Value

45/100

Ref P/E 24.26, PEG 0.63, Graham $6.06

Positives

Low PEG ratio
Forward P/E (14.31) is lower than trailing

Watchpoints

Price is 40% above Graham Number
Price is 246% above Intrinsic Value

Future

60/100

Ref Growth rates and Analyst Targets

Positives

14.5% Revenue growth
Analyst target price of $13.00

Watchpoints

Negative earnings growth
Bearish technicals

Past

75/100

Ref Historical price performance

Positives

Strong 1Y, 3Y, and 5Y price returns
Consistent revenue scaling

Watchpoints

Inconsistent earnings beat record (1/4 last 4 quarters)

Health

90/100

Ref Debt/Equity 0.04, Current Ratio 4.07

Positives

Extremely low Debt/Equity
High Current and Quick ratios

Watchpoints

Piotroski F-Score is only mediocre (4/9)

Dividend

40/100

Ref Yield 2.94%, Strength 20/100

Positives

Positive yield of 2.94%

Watchpoints

Low dividend strength score (20/100)
Payout ratio listed at 0.00% suggests non-standard distribution

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$8.49

Analyst Target

$13.0

Upside/Downside

+53.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for KMDA and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
KMDA Kamada Ltd. Primary	+49.5%	+95.6%	+48.0%	+28.6%	+2.3%	+0.2%
BWAY BrainsWay Ltd. Peer	+163.4%	+1289.2%	+184.8%	+61.0%	-3.2%	-7.8%
AQST Aquestive Therapeutics, Inc. Peer	-27.7%	+432.4%	+47.8%	-20.4%	+5.2%	-4.7%
ANGO AngioDynamics, Inc. Peer	-49.3%	+20.9%	+23.6%	+7.9%	+5.1%	+6.4%
AVR Anteris Technologies Global Corp. Peer	-8.8%	-8.8%	+40.4%	+17.2%	-21.5%	-6.6%

KMD

Kamada Ltd.

Primary

+49.5%

+95.6%

+48.0%

+28.6%

+2.3%

+0.2%

BWA

BrainsWay Ltd.

Peer

+163.4%

+1289.2%

+184.8%

+61.0%

-3.2%

-7.8%

AQS

Aquestive Therapeutics, Inc.

Peer

-27.7%

+432.4%

+47.8%

-20.4%

+5.2%

-4.7%

ANG

AngioDynamics, Inc.

Peer

-49.3%

+20.9%

+23.6%

+7.9%

+5.1%

+6.4%

AVR

Anteris Technologies Global Corp.

Peer

-8.8%

+40.4%

+17.2%

-21.5%

-6.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

24.26

14.31

0.63

1.82

2.72

2.36

10.78

$490.86M

Profitability

Profit margins and return metrics

Profit Margin 11.19%

Operating Margin 7.95%

Gross Margin 42.34%

ROE 7.64%

ROA 4.37%

Growth

Revenue and earnings growth rates

Revenue Growth +14.5%

Earnings Growth -14.1%

Q/Q Revenue Growth +14.54%

Q/Q Earnings Growth -6.5%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.04

Low debt

Current Ratio

4.07

Strong

Quick Ratio

2.2

Excellent

Cash/Share

$1.31

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

38.0%

Op. Margin

7.9%

Net Margin

8.0%

Total Assets

$0.4B

Liabilities

$0.1B

Equity

$0.3B

Debt/Equity

0.41x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

63%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-13

$N/A

2026-03-11

$0.06

-22.6% surprise

2025-11-10

$0.09

-2.7% surprise

2025-08-13

$0.13

+44.4% surprise

Healthcare Sector Comparison

Comparing KMDA against 291 companies in the Healthcare sector (20 bullish, 99 neutral, 172 bearish)

P/E Ratio

24.26

This Stock

87.11

Sector Avg

-72.2% (Discount)

Return on Equity (ROE)

7.64%

This Stock

-49.88%

Sector Avg

-115.3% (Below Avg)

Profit Margin

11.19%

This Stock

-9.43%

Sector Avg

-218.6% (Weaker)

Debt to Equity

0.04

This Stock

3.74

Sector Avg

-98.9% (Less Debt)

Revenue Growth

14.5%

This Stock

80.78%

Sector Avg

-82.0% (Slower)

Current Ratio

4.07

This Stock

3.72

Sector Avg

+9.5% (Better)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
KMDA Kamada Ltd.	NEUTRAL	$490.86M	24.26	7.6%	11.2%	$8.49
BWAY BrainsWay Ltd.	NEUTRAL	$490.8M	68.11	11.3%	14.6%	$12.26	Compare
AQST Aquestive Therapeutics, Inc.	BEARISH	$490.45M	-	-%	-188.1%	$4.02	Compare
ANGO AngioDynamics, Inc.	BEARISH	$492.14M	-	-15.3%	-9.0%	$11.94	Compare
AVR Anteris Technologies Global Corp.	BEARISH	$496.86M	-	-301.9%	-%	$5.11	Compare

KMDA Kamada Ltd.

NEUTRAL

Mkt Cap

$491M

P/E

24.3

ROE

7.6%

Price

$8.49

Compare with KMDA

Compare with KMDA

ANGO AngioDynamics, Inc.

Compare with KMDA

Compare with KMDA

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

4 analysts

HC Wainwright & Co.

2025-12-09

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning KMDA from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

KMDA

KMDA Kamada Ltd. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!